All In Biotech

Drug Trial Radar · NCT06465485

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

STEP: A Prospective, Interventional, Multicenter, Single-Arm Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

504

Actual

Start

Feb 28, 2024

Primary completion

May 13, 2026

Study completion May 13, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to maintain asthma control in Chinese patients.

Conditions

  • Severe Eosinophilic Asthma

Interventions

  • BenralizumabDrug

    Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be enrolled into this single arm treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen in the overall patient populationa and by subgroups of baseline background therapyTime frame: within 40 weeks after the first administration

Locations

74 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chengdu, China

  • Research Site

    Chengdu, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guilin, China

  • Research Site

    Guiyang, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Hefei, China

  • Research Site

    Hohhot, China

  • Research Site

    Hohhot, China

  • Research Site

    Huzhou, China

  • Research Site

    Jinan, China

  • Research Site

    Jinan, China

  • Research Site

    Jinan, China

  • Research Site

    Kunming, China

  • Research Site

    Lanzhou, China

  • Research Site

    Luoyang, China

  • Research Site

    Nanjing, China

  • Research Site

    Nanjing, China

  • Research Site

    Nanning, China

  • Research Site

    Ningbo, China

  • Research Site

    Qingdao, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.